Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
Based on advances in the understanding of the etiology of neurodegeneration, SciNeuro Pharmaceuticals is developing ground-breaking therapies with multi-indication potential.
Approaches to slow or reverse aging have gained momentum in recent years, but the field is still in its infancy with hurdles to overcome, as illustrated by efforts to develop therapies that clear senescent cells.
By taking a neuroanatomy-led gene-therapy approach, AviadoBio is developing targeted drugs and delivery technologies to advance the treatment of neurological conditions such as frontotemporal dementia and amyotrophic lateral sclerosis.
With its first-in-class Cholesterol Degrading Platform (CDP), Repair Biotechnologiesis tackling the root cause of many difficult-to-treat age-related diseases.
NIBEC (the Nano Intelligent Biomedical Engineering Corporation)’s transformative carrier platform is delivering macromolecular drugs to cell and tissue targets throughout the body with improved therapeutic efficacy and reduced side effects.
Deciduous Therapeutics is developing a novel class of immuno-therapies designed to systemically clear senescent cells and to treat co-morbidities of aging.
Achelois BioPharma has built a screening platform to discover T cell-intrinsic genetic-enhancing modifiers that enable tumor-specific T cells to eliminate established tumors in preclinical models and patients.
High-value cell therapy deals are driving investment in the cell and gene therapy field, but new approaches such as gene editing are also beginning to contribute.
Acumen Pharmaceuticals is developing ACU193 as the first clinical-stage therapeutic to selectively target toxic soluble amyloid-β oligomers (AβOs), which are an early and persistent driver of Alzheimer’s disease-related neurodegeneration.
Companies that have pioneered platforms based on oligonucleotides targeting RNA and their biopharma partners continue to move beyond rare diseases into broader patient populations with cardiovascular diseases and central nervous system disorders.
Unique proteolipid vehicle (PLV) technology developed by Entos Pharmaceuticals is broadening the scope for biopharma to deliver nucleic-acid payoffs to target cells throughout the body, paving the way for a new generation of curative drugs.
Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.
Philadelphia’s Aro Biotherapeutics has developed a novel RNA platform that leverages Centyrin proteins to deliver oligonucleotides to muscle and immune cells.
Primrose Bio’s advanced technology for manufacturing nucleic acids and proteins makes it the partner of choice for pharma companies developing new vaccines, therapeutics and bio-based products.
